NCT02016690View on ClinicalTrials.gov

Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®

CompletedOBSERVATIONAL
Enrollment

312

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Respiratory Syncytial Virus Infection
Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY